Notably, the antitumor benefits of Uro A were completely abolished when T-cell populations were depleted using anti-CD4 and anti-CD8 antibodies, indicating the crucial role of T cells in coordinating the antitumor functions of Uro A. Several studies have demonstrated that both CD4+ and CD8+ T cells can promote antitumor immunity by directly killing tumor cells or indirectly activating innate immune cells to mount a robust antitumor response (35). The gene discussed is CD8A; the disease is neoplasm.